Original-Research: MagForce AG (von GBC AG): Buy
Original-Research: MagForce AG (von GBC AG): Buy Einstufung von GBC AG zu MagForce AG Unternehmen: MagForce AG Empfehlung: Buy Letzte Ratingänderung: Analyst: Cosmin Filker, Marcel Goldmann Further results of the pivotal study 2a confirm expectations, market approval in 2021 still in prospect, price target of EUR 11.00 and BUY rating confirmed After MagForce AG announced the successful completion of stage 2a of the pivotal study for the treatment of prostate cancer in the USA in February 2021, the company has published additional, more concrete results on this study phase in a recent ...